Literature DB >> 30448461

ADAR2-dependent A-to-I RNA editing in the extracellular linear and circular RNAs.

Takashi Hosaka1, Takenari Yamashita2, Sayaka Teramoto3, Naoki Hirose3, Akira Tamaoka4, Shin Kwak5.   

Abstract

Currently, no reliable biomarkers of amyotrophic lateral sclerosis (ALS) exist. In sporadic ALS, RNA editing at the glutamine/arginine site of GluA2 mRNA is specifically reduced in the motor neurons due to the downregulation of adenosine deaminase acting on RNA 2 (ADAR2). Furthermore, TDP-43 pathology, the pathological hallmark of ALS, is observed in the ADAR2-lacking motor neurons in ALS patients and conditional ADAR2 knockout mice, suggesting a pivotal role of ADAR2 downregulation in the ALS pathogenesis. Extracellular RNAs were shown to represent potential disease biomarkers and the editing efficiencies at their ADAR2-dependent sites may reflect cellular ADAR2 activity, suggesting that these RNAs isolated from the body fluids may represent the biomarkers of ALS. We searched for ADAR2-dependent sites in the mouse motor neurons and human-derived cultured cells and found 10 sites in five host RNAs expressed in SH-SY5Y cells and their culture medium. Of these, the arginine/glycine site of SON mRNA was newly identified as an ADAR2-dependent site. Furthermore, we detected a circular RNA with an ADAR2-dependent site in the SH-SY5Y cells and their culture medium. Therefore, the changes in the editing efficiencies at the identified host RNA sites isolated from the body fluids may represent potential biomarkers of ALS.
Copyright © 2018 Elsevier B.V. and Japan Neuroscience Society. All rights reserved.

Entities:  

Keywords:  Adenosine deaminase acting on RNA 2 (ADAR2); Amyotrophic lateral sclerosis (ALS); Biomarker; Circular RNA; Extracellular RNA; RNA editing

Mesh:

Substances:

Year:  2018        PMID: 30448461     DOI: 10.1016/j.neures.2018.11.005

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  6 in total

1.  Role of downregulated ADARB1 in lung squamous cell carcinoma.

Authors:  Xiang Wang; Xinxin Ren; Wanli Liu; Xi Chen; Jie Wei; Zhicheng Gong; Yuanliang Yan; Zhijie Xu
Journal:  Mol Med Rep       Date:  2020-01-23       Impact factor: 2.952

Review 2.  A-to-I RNA Editing in Cancer: From Evaluating the Editing Level to Exploring the Editing Effects.

Authors:  Heming Wang; Sinuo Chen; Jiayi Wei; Guangqi Song; Yicheng Zhao
Journal:  Front Oncol       Date:  2021-02-11       Impact factor: 6.244

Review 3.  RNA Editing: A New Therapeutic Target in Amyotrophic Lateral Sclerosis and Other Neurological Diseases.

Authors:  Takashi Hosaka; Hiroshi Tsuji; Shin Kwak
Journal:  Int J Mol Sci       Date:  2021-10-11       Impact factor: 5.923

Review 4.  Roles of Major RNA Adenosine Modifications in Head and Neck Squamous Cell Carcinoma.

Authors:  Xing-Xing Huo; Shu-Jie Wang; Hang Song; Ming-de Li; Hua Yu; Meng Wang; Hong-Xiao Gong; Xiao-Ting Qiu; Yong-Fu Zhu; Jian-Ye Zhang
Journal:  Front Pharmacol       Date:  2021-11-25       Impact factor: 5.810

5.  Mechanism of the Curative Effect of Wen-Shen-Jian-Pi Prescription in the Treatment of Amyotrophic Lateral Sclerosis.

Authors:  Fan Gong; Wei Zhu; Weilong Liao; Mingzhe Wang; Xuanlu Zheng; Chenghui Wang; Te Liu; Weidong Pan
Journal:  Front Aging Neurosci       Date:  2022-04-08       Impact factor: 5.750

6.  A comparative analysis of ADAR mutant mice reveals site-specific regulation of RNA editing.

Authors:  Pedro Henrique Costa Cruz; Yuki Kato; Taisuke Nakahama; Toshiharu Shibuya; Yukio Kawahara
Journal:  RNA       Date:  2020-01-15       Impact factor: 4.942

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.